Advanced search
Publication Cover
Current Medical Research and Opinion Volume 23, 2007 - Issue sup1: Insulin glargine for the treatment of T1 and T2 diabetes / Guest Editors: S Dixon and J R Peters
Submit an article Journal homepage
126
Views
21
CrossRef citations to date
0
Altmetric
Original Article

The outcome of care in people with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis

Craig J. Currie Department of Medicine, School of Medicine, Cardiff University, Cardiff, UKCorrespondence[email protected]
,
Chris D. Poole Cardiff Research Consortium, Heath Park, Cardiff, UK
,
Tony Tetlow Cardiff Research Consortium, Heath Park, Cardiff, UK
,
Paul Holmes sanofi-aventis UK, Guildford, Surrey, UK
&
Phil McEwan School of Mathematics, Cardiff University, Cardiff, UK
Pages S33-S39 | Accepted 11 Jan 2007, Published online: 07 Feb 2007

Citations (21)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Odd Erik Johansen, Pål Johan Vanberg, Bente Kvarv Kilhovd & Anders Palmstrøm Jørgensen. (2009) Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia. Vascular Health and Risk Management 5, pages 121-128.
Read now
Manuela Helena Gschwend, Mark Aagren & William J Valentine. (2009) Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countries. Journal of Medical Economics 12:2, pages 114-123.
Read now
Cecilia M Lansang & Laurence Kennedy. (2007) Insulin glargine: a basal insulin for the management of diabetes. Expert Review of Endocrinology & Metabolism 2:5, pages 573-585.
Read now
Phil McEwan, Chris D. Poole, Tony Tetlow, Paul Holmes & Craig J. Currie. (2007) Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK. Current Medical Research and Opinion 23:sup1, pages S21-S31.
Read now
Simon Dixon & John R. Peters. (2007) Evaluating the ‘real’ cost-effectiveness of health technology: reconciling the public interest with patients’ interests. Current Medical Research and Opinion 23:sup1, pages S1-S6.
Read now

Articles from other publishers (16)

Njabulo Ncube, Elena Kulinskaya, Nicholas Steel & Dmitry Pchejetski. (2022) On the survival of individuals diagnosed with type 2 diabetes mellitus in the United Kingdom: A retrospective matched cohort study. Diabetes Epidemiology and Management 6, pages 100065.
Crossref
Chi-Kin Yeung, Fhkcp Fhkam, Wilson Wai-man Ngai & Ip-tim Lau. (2017) Effect of Initiation of Basal Insulin Glargine on Glycemic Control in Patients with Diabetes: Real Life Experience from Hong Kong. Journal of Diabetes Mellitus 07:03, pages 108-120.
Crossref
M. Dąbrowski. (2014) The outcome of care in people with type 1 diabetes after switching to insulin glargine-based regimens in a real-life setting: a long-term observational study. International Journal of Clinical Practice 68:8, pages 1020-1028.
Crossref
R. F. Pollock, G. Muduma & W. J. Valentine. (2012) Evaluating the cost‐effectiveness of laparoscopic adjustable gastric banding versus standard medical management in obese patients with type 2 diabetes in the UK . Diabetes, Obesity and Metabolism 15:2, pages 121-129.
Crossref
F. ?lvarez Guisasola, D. Mauricio Puente, T. Garc?a Coscol?n, L. Beteg?n Nicol?s & C. Rubio-Terr?s. (2010) An?lisis de costes del tratamiento de la diabetes mellitus tipo 2 con insulina glargina o detemir. Avances en Diabetolog?a 26:6, pages 430-435.
Crossref
Satish GargEmily MoserMarie-Paule DainAnastasia Rodionova. (2010) Clinical Experience with Insulin Glargine in Type 1 Diabetes. Diabetes Technology & Therapeutics 12:11, pages 835-846.
Crossref
Marc L Evans, Peter Sharplin, David R Owens, George H Chamberlain, Andrea J Longman & Philip McEwan. (2010) Insulin usage in type 2 diabetes mellitus patients in UK clinical practice: a retrospective cohort-based analysis using the THIN database. The British Journal of Diabetes & Vascular Disease 10:4, pages 178-182.
Crossref
Peter Sharplin, Jason Gordon, John R Peters, Anthony P Tetlow, Andrea J Longman & Philip McEwan. (2009) Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary care-based analysis. Cardiovascular Diabetology 8:1.
Crossref
Peter Sharplin, Jason Gordon, John R Peters, Anthony P Tetlow, Andrea J Longman & Philip McEwan. (2009) Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study. Cardiovascular Diabetology 8:1.
Crossref
C. Pratoomsoot, H. T. Smith, A. Kalsekar, K. S. Boye, J. Arellano & W. J. Valentine. (2009) An estimation of the long‐term clinical and economic benefits of insulin lispro in Type 1 diabetes in the UK. Diabetic Medicine 26:8, pages 803-814.
Crossref
Julia M. Bottomley & Frank D. Raymond. (2009) Pharmaco-economic issues for diabetes therapy. Insulin 4:1, pages 32-60.
Crossref
Andrew Maguire, Betina T. Blak & Mary Thompson. (2008) The importance of defining periods of complete mortality reporting for research using automated data from primary care. Pharmacoepidemiology and Drug Safety 18:1, pages 76-83.
Crossref
. (2008) Current World Literature. Current Opinion in Endocrinology, Diabetes & Obesity 15:4, pages 383-400.
Crossref
S. A. Schreiber. (2008) Insulin glargine in type 2 diabetes in everyday clinical practice: 7 years experience. Diabetes, Obesity and Metabolism 10:s2, pages 24-34.
Crossref
Julia M. Bottomley & Frank D. Raymond. (2007) Pharmaco-economic issues for diabetes therapy. Best Practice & Research Clinical Endocrinology & Metabolism 21:4, pages 657-685.
Crossref
. (2013) Insulin glargine adds up to value for diabetes in the UK. PharmacoEconomics & Outcomes News 528:1, pages 3-4.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.